This inventor holds 3 USPTO granted patents. Top assignees: Hsc Research and Development Limited Partnership, Telios Pharmaceuticals, Inc.. Active years: 1998-2000.
Company Filing History:
2 out of 36 
1 out of 1 Years Active: 1998-2000
Title: Sela Cheifetz: Innovator in TGF-β-Binding Glycoproteins
Introduction
Sela Cheifetz is a notable inventor based in Concord, CA, recognized for his contributions to the field of biotechnology. He holds three patents that focus on the recombinant production of soluble TGF-β-binding endoglin and related compositions. His work has significant implications for pharmaceutical applications and patient treatment methodologies.
Latest Patents
One of Sela Cheifetz's latest patents is titled "Recombinant production of soluble TGF-β-binding endoglin." This invention provides a novel purified TGF-β-binding glycoprotein known as endoglin. It includes an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-β-binding glycoprotein, as well as soluble endoglin-derived polypeptides and fragments thereof. The patent also describes a pharmaceutical composition that comprises the endoglin-derived polypeptide, purified by the applicants or produced through their recombinant methods, along with a pharmaceutically acceptable carrier. Additionally, methods for treating patients using this pharmaceutical composition are outlined.
Another significant patent by Cheifetz is "Soluble TGF-β-binding endoglin polypeptides and homodimers." Similar to his previous work, this invention also focuses on the purification and application of the TGF-β-binding glycoprotein endoglin. It emphasizes the importance of the endoglin-derived polypeptide and its potential in therapeutic settings.
Career Highlights
Throughout his career, Sela Cheifetz has worked with various organizations, including HSC Research and Development Limited Partnership and Telios Pharmaceuticals, Inc. His experience in these companies has contributed to his expertise in the field of biotechnology and patent development.
Collaborations
Sela Cheifetz has collaborated with notable professionals in his field, including Michelle Letarte and Joan Massague. These collaborations have likely enriched his research and innovation efforts.
Conclusion
Sela Cheifetz is a prominent inventor whose work in TGF-β-binding glycoproteins has the potential to advance pharmaceutical treatments. His patents reflect a commitment to innovation and improving patient care through biotechnology.